Iso 13739

[Florio Bessinger]

The2018 United States Supreme Court decision in South Dakota v. Wayfair, Inc. has impacted many state nexus laws and sales tax collection requirements. To review these changes, visit our state-by-state guide.

Automating sales tax compliance can help your business keep compliant with changing sales tax laws. AvaTax delivers real-time sales tax rates and uses advanced technology to map rates to exact address locations, based on the latest jurisdiction requirements.

NOTE: The outbreak of COVID-19 (caused by the coronavirus) may have impacted sales tax filing due dates in 13739. Please consult your local tax authority for specific details. For more information, visit our ongoing coverage of the virus and its impact on sales tax compliance.

We are providing this information because the importance of a suitably drawn and witnessed representative sample cannot be over-emphasized. The commercial sample forms the basis of all product quality dispute resolutions between a supplier and customer, and the MARPOL sample provides product quality evidence to Port State Control Authorities, if required.

ExxonMobil maintains a Sampling Policy based on sound bunkering principles, MARPOL Annex VI resolution MEPC.182(59) as well as Industry Standards (ISO 13739). It covers the method of taking the sample, location and witnessing.

Special care must be taken to ensure that new, unused containers are used for sampling. Prior to the commencement of bunkering, the sampling device must be cleaned or flushed to ensure no sample contamination can occur from previous products. Personnel must ensure that no rain or debris is allowed to contaminate the samples. Each sample must be sealed with the seal identification number listed on the product delivery Bunker Delivery Note (BDN).

Commercial samples should be retained for evidentiary purposes for a period of no less than 90 days from the date of delivery. MARPOL samples must be retained on board until the fuel is substantially consumed; but in any case, for a period of no less than 12 months from the time of delivery. The MARPOL sample can only be released by the Port State Control Authorities or Flag State administration authorities, and it shall be analysed in accordance with the verification procedure set forth in Appendix VI of the Revised MARPOL Annex VI.

Asbury Green

MSA SC 3520-13739

Lynched in Centreville, Maryland on May 13, 1891Biography1:Asbury Green, an African American man, was lynched in Centreville, May13, 1891. He was accused of the assault on Mrs. Howard Tolsen. Mrs. Tolsen was thewife of a farmer residing on Kent Island, Queen Anne's County, Maryland. Her husband was away onbusiness when she claimed Green entered her home around 9:30 p.m. on February28, 1891. Green was arrested the following day and placed in thecounty jail to await trial. An investigation was conducted, and atthe preliminary hearing, Green was charged with "assault with intentto rape," as Tolsen allegedly did not want to disclose the fact that she had been raped by her attacker. It was not until evidence was exposed during a grand jury trail that all events surrounding the attack wereknown. Green's trial was held with Judges Robinson, Wickes and Stump presiding. On the behalf of Green's defense, several men testified that they could account for Green's whereabouts during the time of the alleged assault. However, the jury was not convinced. The trial lasted one day and Green was found guilty on the charge of rape. He was sentenced to 21-years of confinement and hard labor in the state penitentiary. Many citizens in the town were outraged that Green had not been sentenced to death. The court did not sentence Green to death because there was doubt that Green was the true attacker.2 At the end of the court proceedings, there were several rumors that Green would be lynched.Sheriff Thomas B. Turner increased the number of guards at the jailhouse in case there was an attempt to lynch Green. The Sheriff added seven more guards to the night shift. However, this measure did not protect Green. Around 1:00 a.m. the morning of May 13, there was a call from the outside gate of the jail. When Deputy Sheriff Seward went out to investigate, a mob of men rushed at him and demanded the keys to the jail. When Seward refused, the mob threw him down and forcibly took the keys. The mob entered the jail armed with guns, pistols, rifles, and axes, commanding the guards to keep quiet. The men unlocked the cell, placed a rope around Green's neck, and hauled him outside.Green was dragged to a nearby orchard. The mob acquired a rope and then hung him by the neck from a peach tree. Witnesses believed Green was half dead when the mob reached the orchard. The crowd of 150 to 250 men quickly and quietly dispersed. On Tuesday, a jury of inquest was summoned and their verdict follows: "Certain parties, feloniously, voluntarilyand of malice aforethought, dragged from the county jail the said AsburyGreen did kill by strangulation and dislocation of the spinal column andby hanging to a tree, said parties being to the jury unknown, and did thenand there kill and murder the said Asbury Green"The body of Asbury Green was buried the following Wednesday by the local authorities. The 200 African Americans residents in Centreville were understandably outraged by the lynching. Talk of vengence reportedly circulated and the town of 1,400 was tense and freightened that night.3 The citizens of Centreville claimed they were not responsible for the lynching, believing that the mob came from out of town. The Good Will Fire Company patrolled the townto ensure peace. Regardless of the threats, no retaliation was reported after the lynching.

Linkto Lynching Profile QuestionnaireReturnto Introductory Page

This web site is presented for reference purposes under the doctrine of fair use. When this material is used, in whole or in part, proper citation and credit must be attributed to the Maryland State Archives. PLEASE NOTE: The site may contain material from other sources which may be under copyright. Rights assessment, and full originating source citation, is the responsibility of the user.Tell Us What You Think About the Maryland State Archives Website!

This double-blind placebo-controlled paralleled study randomized 302 patients with type 2 diabetes (mean A1C 8.3%) on metformin monotherapy (mean 1.5 g/day) to receive one of five INCB13739 doses or placebo once daily for 12 weeks. The primary end point was the change in A1C at study end. Other end points included changes in fasting glucose, lipids, weight, adverse events, and safety.

INCB13739 added to ongoing metformin therapy was efficacious and well tolerated in patients with type 2 diabetes who had inadequate glycemic control with metformin alone. 11βHSD1 inhibition offers a new potential approach to control glucose and cardiovascular risk factors in type 2 diabetes.

INCB13739 is an oral and selective 11βHSD1 inhibitor being developed to treat type 2 diabetes. We conducted a 12-week dose-ranging study of INCB13739 added to ongoing metformin monotherapy in patients with type 2 diabetes to evaluate the safety and efficacy of this compound.

This was a double-blind randomized paralleled trial conducted at 74 sites in the U.S. and six sites in Puerto Rico (NCT00698230). The study consisted of five periods: screening, metformin dose stabilization, 14-day placebo single-blind run-in, 12-week double-blind treatment, and 3-week off-treatment follow-up. The study was conducted pursuant to the Declaration of Helsinki and was approved by institutional review boards at participating sites. Patients provided informed consent before screening.

Patients were randomized equally to once-daily INCB13739 (5, 15, 50, 100, or 200 mg) or placebo. Dose selection was based on phase 1 pharmacokinetic and pharmacodynamic data, with the goal of evaluating regimens that achieve different degrees of inhibition, from 90%, with the duration of inhibition varying across the five dose levels. Patients with a fasting plasma glucose (FPG) >270 mg/dl through week 8 or >240 mg/dl subsequently were discontinued and offered rescue therapy.

On-treatment study visits occurred at weeks 2, 4, 8, and 12 and a follow-up visit at week 15 off treatment. Fasting blood samples were collected after a minimum 10-h fast. Salivary samples were collected between 2200 and 2400. All assays were performed by Covance Central Labs. Monitoring for adverse events (AEs) (intensity, duration, outcome, and causality), physical examinations, vital signs, body weight and morphometrics, 12-lead electrocardiograms, and safety laboratory assessments including hematology, serum chemistry, and urinalysis were also performed.

For all end points, treatment effect was assessed using a linear model with treatment as the model factor and baseline as a covariate. Changes from baseline were estimated with 90% CIs from the model.

Endocrine data are week 12 LS mean SEM unless otherwise noted. Androgens and their precursors are categorized by sex. Central lab normal reference ranges are provided. Treatment emergent AE data are n (%) for all AEs or for those occurring in at least 3% of patients. A4, androstenedione; d/c, discontinuation; FAI, free androgen index; SAE, serious adverse event; T, testosterone.

The results from this study indicate, for the first time, that decreasing local cortisol exposure through 11βHSD1 inhibition improves hyperglycemia over 12 weeks in patients with type 2 diabetes. The addition of once-daily INCB13739 in patients inadequately controlled with metformin significantly reduced A1C, FPG, and HOMA-IR. These effects were dose dependent, and the greatest improvements were achieved at the highest dose administered (200 mg), with evidence for a more profound A1C reduction in subjects with a BMI >30 kg/m2, compatible with elevated 11βHSD1 in adipose tissue in obesity. Preliminary data from pharmacokinetic analyses (data not shown) indicate that the 100- and 200-mg groups achieved, 4 h after administration, mean free drug exposures that reached 100 mg or exceeded 200 mg, the concentrations required to inhibit 90% of the enzyme activity in cellular assays; however, only the 200-mg group retained such a mean exposure at the end of the dosing interval. Thus, glycemic efficacy may be associated with a high degree of enzyme inhibition, and it is possible that greater glycemic improvement might be achieved with increased dose levels or frequency of administration.

3a8082e126